Abstract:
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) found that intermittent infusions of IL-2, an immune system protein, boosted T-cells in some patients with HIV for more than two years--far longer than any current antiretroviral. NIAID studied the effects of intravenous IL-2 in combination with AZT or ddI in 25 people with HIV or AIDS. Of the ten patients with T-cell counts greater than 200 who started the study, six had increases of more than fifty percent after one year. Alternately, of the fifteen patients who started the study with T-cell counts fewer than 200, only two patients showed a fifty percent increase in cell counts. Side effects were considerably more pronounced in the remaining thirteen participants in that group, and no significant increases in T-cell counts were observed. IL-2 is a naturally occurring substance produced by the body. However, NIAID used recombinant DNA technology produced by Chiron Corporation in Emeryville, California for its studies. Several IL-2 clinical trials are currently enrolling.
Keywords: Clinical Trials CD4 Lymphocyte Count Didanosine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Drug Therapy, Combination Human HIV Infections/DRUG THERAPY/IMMUNOLOGY/*THERAPY Interleukin-2/ADVERSE EFFECTS/*THERAPEUTIC USE Zidovudine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE NEWSLETTER ARTICLE 951230
M95C3194
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.